Phaseline

Targets › KRAS

KRAS (GTPase KRas): drug programs, companies and trials

107 programs from 74 companies in 279 trials: 145 Phase 1, 88 Phase 2, 45 Phase 3, 1 Phase 4; Oncology, Other, Immunology; next expected readout Nov 2026.

Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. (UniProt, P01116)

Open in Phaseline: the race on KRAS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Aarhus University HospitalEnstilar
Topical combination (calcipotriol + betamethasone dipropionate)
KRASPhase 4Psoriasis VulgarisDec 2026
Bristol-Myers SquibbAdagrasib
GTPase KRas inhibitor
KRASPhase 3Metastatic Non Small Cell Lung Cancer; Advanced Colorectal Cancer; Carcinoma, Non-Small-Cell Lung; Advanced Cancer …Nov 2026
Allist PharmaceuticalsJAB-21822
KRAS G12C inhibitor
KRASPhase 3Advanced Non-squamous Non-small-cell Lung Cancer; KRAS P.G12C; Advanced Colorectal Cancer; NSCLC …Dec 2026
AmgenSotorasib
GTPase KRas inhibitor
KRASPhase 3Non-Small Cell Lung Cancer (NSCLC); Metastatic Colorectal Cancer; Advanced Solid Tumors; Lung Adenocarcinoma …Dec 2026
Revolution MedicinesRMC-6236
RAS(ON) inhibitor - KRAS G12C inhibitor
KRASPhase 3Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC; Colorectal CancerDec 2026
IncyteINCB161734
KRAS G12D inhibitor
KRASPhase 3Solid Tumors; Healthy ParticipantsJan 2027
NovartisJDQ443
KRAS G12C inhibitor
KRASPhase 3Non-Small Cell Lung Cancer; Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation; KRAS G12C Mutant Solid Tumors; NSCLCJan 2027
Jiangsu HengRui MedicineHRS-4642
KRAS G12D inhibitor
KRASPhase 3KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting; Advanced KRAS G12D Mutant Solid Tumors; Advanced Solid Tumors; Metastatic Pancreatic Carcinoma …Mar 2027
Eli LillyOlomorasib (LY3537982)
KRAS G12C inhibitor
KRASPhase 3Carcinoma, Non-Small-Cell Lung; Healthy VolunteersApr 2027
AstellasSetidegrasib (ASP3082)
KRAS G12D inhibitor
KRASPhase 3Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Healthy VolunteerMay 2027
Genfleet Therapeutics (Shanghai)Cetuximab (GFH375)
KRAS G12D inhibitor
KRASPhase 3Metastatic Pancreatic Cancer; KRAS G12D Mutation; Pancreatic Cancer; Advanced Solid Tumors Cancer …Jun 2027
Revolution MedicinesDaraxonrasib
KRAS(ON) inhibitor
KRASPhase 3NSCLC (Non-small Cell Lung Cancer); Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer (NSCLC) …Dec 2027
Chia Tai Tianqing Pharmaceutical GroupD-1553 Tablet
KRAS G12C inhibitor
KRASPhase 3Non Small Cell Lung CancerDec 2027
InxMed (Shanghai)D-1553
KRAS G12C inhibitor
KRASPhase 3Non-Small Cell Lung Cancer; Solid TumorDec 2027
Merck & Co. (MSD)Calderasib (MK-1084)
KRAS G12C inhibitor
KRASPhase 3Non-small Cell Lung Cancer; Colon Adenocarcinoma; Malignant Neoplasm; Neoplasm Malignant …Jan 2028
RocheDivarasib
KRAS G12C inhibitor
KRASPhase 3Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Metastatic Colorectal CancerNov 2028
Revolution MedicinesZoldonrasib
KRAS(ON) inhibitor
KRASPhase 3Pancreatic Cancer; NSCLC; Advanced Solid TumorsDec 2028
Ranok Therapeutics (Hangzhou)RNK08954
KRAS G12D inhibitor
KRASPhase 2KRAS G12D MutationsNov 2026
Shandong Suncadia MedicineHRS-7058
KRAS G12C selective inhibitor
KRASPhase 2Advanced Malignant Tumour; Solid Tumors; Pancreatic CancerDec 2026
Guangzhou JOYO PharmaJYP0015
Pan-RAS inhibitor targeting the active (ON) form of wild-type and mutant RAS
KRAS, NRAS, HRASPhase 2Solid TumorDec 2026
Georgetown UniversityKRAS vaccine
KRAS-directed cancer vaccine (Targovax TG01 with Stimulon QS-21 adjuvant)
KRASPhase 2Pancreatic Ductal AdenocarcinomaJun 2027
VerastemVS-7375
KRAS G12D inhibitor
KRASPhase 2Colorectal Cancer; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Ductal AdenocarcinomaJun 2027
Abbisko TherapeuticsABSK043
KRAS inhibitor
KRASPhase 2Non-Small Cell Lung Cancer With EGFR Mutation; Non-Small Cell Lung Cancer; NeoplasmsJul 2027
Gustave Roussy, Cancer Campus, Grand ParisASP3082
KRAS G12D inhibitor
KRASPhase 2Metastatic/Locally Advanced Non-Small-Cell Lung CancerSep 2027
Guangdong Association of Clinical TrialsIBI351
KRAS G12C inhibitor
KRASPhase 2Lung Cancer (Non-Small Cell)Sep 2027
Guangdong Provincial People's HospitalGarsorasib
KRAS G12C inhibitor
KRASPhase 2Lung Cancer (NSCLC)Dec 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineGlecirasib
KRAS G12C inhibitor
KRASPhase 2NSCLCJan 2028
Bristol-Myers SquibbDaraxonrasib (RMC-6236)
KRAS inhibitor
KRASPhase 2Solid TumorsAug 2028
Jeeyun LeeRilvegostomig
KRAS G12D inhibitor
KRASPhase 2Stomach NeoplasmsOct 2028
Zhejiang Universityfulzerasib
KRAS G12C inhibitor
KRASPhase 2Colorectal CancerDec 2028
Elicio TherapeuticsELI-002 7P
Lipid-conjugated CpG oligonucleotide (Amph-CpG-7909) plus lipid-conjugated peptide-based a
KRAS, NRASPhase 1Pancreatic Ductal Adenocarcinoma; Pancreatic CancerNov 2026
Boehringer IngelheimBI 1701963
KRAS reactivation inhibitor
KRASPhase 1Solid Tumors, KRAS Mutation; Solid Tumors, KRAS Mutation; SOS1Nov 2026
Boehringer IngelheimBI 1823911
KRAS inhibitor
KRASPhase 1Solid Tumors, KRAS MutationNov 2026
ArvinasARV-806
KRAS G12D degrader (targeted protein degradation)
KRASPhase 1KRAS G12D MutationNov 2026
Sichuan Huiyu PharmaceuticalHYP-2090PTSA
KRAS G12C inhibitor
KRASPhase 1SafetyDec 2026
PAQ TherapeuticsPT0253
KRAS G12D inhibitor
KRASPhase 1Solid TumorDec 2026
Ranok Therapeutics (Hangzhou)RNK08954-01
KRAS G12D inhibitor
KRASPhase 1KRAS G12D MutationDec 2026
HUYABIO InternationalHBI-2438
KRAS G12C inhibitor
KRASPhase 1Lung CancerDec 2026
Jacobio PharmaceuticalsJAB-23E73
Pan-KRAS inhibitor
KRASPhase 1Advanced Solid Tumor; Advanced Solid Tumors; Metastatic Pancreatic Ductal AdenocarcinomaDec 2026
PharosgenMPD-1
Doxorubicin prodrug targeting KRAS mutant/PTEN loss advanced cancer
KRAS, PTENPhase 1CancerDec 2026
Revolution MedicinesRMC-9805
RAS(ON) inhibitor - KRAS inhibitor
KRASPhase 1Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC; Colorectal CancerDec 2026
Quanta TherapeuticsQTX3544
KRAS G12V inhibitor
KRASPhase 1Advanced Solid TumorsJan 2027
Zhejiang UniversityNW-301VT
T Cell Receptor (TCR)-engineered T cell therapy targeting KRAS G12V mutation with dominant
KRASPhase 1TumorFeb 2027
Kumquat BiosciencesKQB548
KRAS G12D inhibitor
KRASPhase 1Solid Tumor MalignanciesMar 2027
IncyteINCB186748
KRAS G12D inhibitor
KRASPhase 1Solid TumorsMar 2027
Sun Yat-sen UniversityIX001 TCR-T injection
TCR-T cell therapy targeting KRAS G12V mutation
KRASPhase 1Pancreatic CancerMar 2027
Revolution MedicinesRMC-6291
KRAS(ON) inhibitor
KRASPhase 1Non-Small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLCMar 2027
Quanta TherapeuticsQTX3034
KRAS G12D inhibitor
KRASPhase 1Solid TumorsApr 2027
Henan Cancer HospitalRE002 T cell
TCR-engineered T cell therapy targeting KRAS G12D mutation
KRASPhase 1KRAS G12DApr 2027
Ting DengNW-301D
T cell receptor (TCR)-engineered T cell therapy targeting KRAS G12D mutation
KRASPhase 1Tumor, SolidApr 2027
Ting DengNW-301V
T cell receptor (TCR)-engineered T cell therapy targeting KRAS G12V mutation
KRASPhase 1Tumor, SolidApr 2027
D3 Bio (Wuxi)D3S-001
KRAS G12C inhibitor
KRASPhase 1KRAS P.G12CApr 2027
M.D. Anderson Cancer CenterMesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
KRAS G12D-targeted siRNA delivered via mesenchymal stromal cell-derived exosomes
KRASPhase 1KRAS NP_004976.2:p.G12DApr 2027
Qilu PharmaceuticalQLC1101
KRAS G12D inhibitor
KRASPhase 1Non-small Cell Lung CancerApr 2027
Tyligand Pharmaceuticals (Suzhou)TSN1611
KRAS G12D inhibitor
KRASPhase 1Malignant NeoplasmApr 2027
Oslo University HospitalTG01/QS-21
KRAS/NRAS mutation-specific peptide vaccine with QS-21 adjuvant
KRAS, NRASPhase 1Multiple MyelomaMay 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMutant KRAS peptide vaccine
KRAS mutant-targeted long peptide vaccine
KRASPhase 1Colorectal Cancer; High Risk CancerJun 2027
Changhai HospitalMutant KRAS G12V-specific TCR transduced autologous T cells
TCR-engineered T cells targeting mutant KRAS G12V mutation in HLA-A*11:01 context
KRASPhase 1Pancreatic CancerJun 2027
TingBo LiangNW-301D
TCR-T cell targeting KRAS G12D mutation
KRASPhase 1Tumor, SolidJun 2027
TingBo LiangNW-301V
TCR-T cell targeting KRAS G12V mutation
KRASPhase 1Tumor, SolidJun 2027
Tango TherapeuticsRMC-9805
RAS(ON) G12D selective covalent inhibitor
KRASPhase 1PDACJun 2027
Tao ZhangNW-301D
TCR-T cell targeting KRAS G12D mutation
KRASPhase 1Tumor, SolidJun 2027
Tao ZhangNW-301V
TCR-T cell targeting KRAS G12V mutation
KRASPhase 1Tumor, SolidJun 2027
Quanta TherapeuticsQTX3046
KRAS G12D inhibitor
KRASPhase 1Advanced Solid TumorJul 2027
Innovent Biologics (Suzhou)IBI351
KRAS G12C inhibitor
KRASPhase 1Advanced Non-Small Cell Lung CancerJul 2027
Vividion TherapeuticsVVD-159642
RAS-PI3Kα inhibitor
KRAS, PIK3CAPhase 1Advanced Solid TumorsAug 2027
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)BBO-10203
PI3Kα:RAS breaker
PIK3CA, KRAS, NRAS, HRASPhase 1Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung CancerAug 2027
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)BBO-11818
pan-KRAS inhibitor
KRASPhase 1Non-Small Cell Lung CancerAug 2027
Frontier MedicinesFMC-376
KRAS G12C inhibitor
KRASPhase 1Advanced Solid Tumors With KRAS G12C MutationsOct 2027
InventisBioD-1553
KRAS G12C inhibitor
KRASPhase 1Solid TumorDec 2027
RocheGDC-6036
KRAS G12C inhibitor
KRASPhase 1Non-Small Cell Lung CancerDec 2027
Sichuan UniversityKRAS-mutated mRNA vaccine
mRNA vaccine targeting KRAS mutations
KRASPhase 1Malignant TumorsDec 2027
D3 Bio (Wuxi)D3S-003
KRAS G12D inhibitor
KRASPhase 1KRAS P.G12DJan 2028
Adlai Nortye BiopharmaAN9025
Pan-RAS inhibitor that binds cyclophilin A (CypA) and forms a tri-complex with GTP-bound R
KRAS, NRAS, HRASPhase 1Solid Tumors (Phase 1)Jan 2028
Eli LillyLY3962673
KRAS G12D inhibitor
KRASPhase 1Pancreatic Ductal AdenocarcinomaMar 2028
Kestrel Therapeutics, Inc.KST-6051
KRAS inhibitor
KRASPhase 1KRAS-mutant Non-small Cell Lung Cancer (NSCLC)Apr 2028
AmgenAMG 410
KRAS G12C inhibitor
KRASPhase 1KRAS Altered Advanced or Metastatic Solid TumorsApr 2028
Jiangsu HengRui MedicineHRS-6093
KRAS G12D inhibitor
KRASPhase 1Advanced KRAS G12D Mutant Solid TumorsMay 2028
RocheGDC-7035
KRAS G12D inhibitor
KRASPhase 1Solid TumorMay 2028
Institut de Recherches Internationales ServierS241656
RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III)
BRAF, CRAF, KRAS, NRASPhase 1Non-small Cell Lung CancerJun 2028
ErascaERAS-4001
KRAS inhibitor
KRASPhase 1Metastatic Solid TumorsAug 2028
Genuine Seed Therapeutics (Zhuhai)GST101
KRAS inhibitor
KRASPhase 1RAS-mutant Advanced Solid TumorsOct 2028
PAQ TherapeuticsPT0511
KRAS inhibitor
KRASPhase 1Colorectal CancerOct 2028
Ensem TherapeuticsETX-929
pan-KRAS inhibitor
KRASPhase 1Metastatic Colorectal Cancer (CRC)Oct 2028
AstellasASP5834
KRAS mutant inhibitor
KRASPhase 1Solid TumorNov 2028
Corregene BiotechnologyKRAS-specific Autologous TCR-T cell injection (CRTKVA11-N04)
KRAS G12V-specific T-cell receptor engineered T-cell therapy
KRASPhase 1ColorectalNov 2028
Johnson & Johnson (Janssen)Olomorasib
KRAS G12C inhibitor
KRASPhase 1Carcinoma, Non-Small-Cell LungNov 2028
Revolution MedicinesElironrasib
KRAS(ON) inhibitor
KRASPhase 1Non-Small Cell Lung Cancer (NSCLC); Advanced Solid TumorsDec 2028
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSLP mKRASvax with Poly-ICLC adjuvant
Synthetic long peptide vaccine targeting mutant KRAS with Poly-ICLC (TLR3 agonist) adjuvan
KRASPhase 1Pancreatic Cancer; Colorectal CancerDec 2028
Adlai Nortye BiopharmaAN4035
CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload
CEACAM5, KRAS, NRAS, HRASPhase 1Solid Tumor (Phase I)Dec 2028
National Cancer Institute (NCI)GRT-C903/GRT-R904
Vaccine directed against KRAS mutation antigens
KRASPhase 1Metastatic Solid CancersFeb 2029
Shenzhen Ionova Life SciencesINV-8989
KRAS G12D inhibitor
KRASPhase 1Advance Solid TumorsMay 2029
NovartisOpnurasib
KRAS inhibitor
KRASPhase 1Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerJun 2029
National Cancer Institute (NCI)Anti-KRAS G12V mTCR PBL
Murine T-cell receptor recognizing KRAS G12V variant
KRASPhase 1Pancreatic CancerJun 2029
BayerBAY 3771249
KRAS G12D inhibitor
KRASPhase 1Advanced/Metastatic Colorectal AdenocarcinomaJul 2029
Blueprint MedicinesBLU-924 (SAR449336)
pan-KRAS inhibitor
KRASPhase 1Advanced Solid TumorSep 2029
Daiichi SankyoOlomorasib
KRAS G12C inhibitor
KRASPhase 1Urothelial CancerSep 2029
Affini-T TherapeuticsAFNT-211
Engineered TCR T-cell recognizing KRAS G12V
KRASPhase 1Pancreatic Ductal AdenocarcinomaDec 2029
Abbisko TherapeuticsABSK211
KRAS inhibitor
KRASPhase 1Solid Tumor (Phase I)Dec 2029
Eli LillyLY4066434
Pan-KRAS inhibitor
KRASPhase 1Pancreatic Ductal AdenocarcinomaJan 2030
Anocca ABANOC-001
TCR-engineered T cells targeting KRAS G12V mutation presented by specific HLA alleles
KRASPhase 1PDACApr 2030
Anocca ABANOC-002
TCR-engineered T cells targeting KRAS G12V mutation presented by specific HLA alleles
KRASPhase 1PDACApr 2030
Anocca ABANOC-003
TCR-engineered T cells targeting KRAS G12D mutation presented by specific HLA alleles
KRASPhase 1PDACApr 2030
Memorial Sloan Kettering Cancer CenterMSK-TCR5
T cell receptor (TCR) engineered to recognize RAS G12D mutations
KRAS, HRAS, NRASPhase 1Solid TumorJun 2030
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)BBO-8520
KRAS G12C ON and OFF inhibitor
KRASPhase 1Non-small Cell Lung CancerApr 2031
PfizerPF-07934040
panKRAS inhibitor
KRASPhase 1Carcinoma, Pancreatic Ductal–
Shanghai YingLi PharmaceuticalYL-17231
Pan-RAS inhibitor
KRAS, HRAS, NRASPhase 1Advanced Solid Tumors–

Conditions

Colorectal Cancer (16) Pancreatic Cancer (15) Non-small Cell Lung Cancer (11) Non-Small Cell Lung Cancer (11) Advanced Solid Tumors (11) Metastatic Colorectal Cancer (9) Solid Tumors (7) Solid Tumor (7) Pancreatic Ductal Adenocarcinoma (6) Tumor, Solid (6) Head and Neck Cancer (6) Carcinoma, Non-Small-Cell Lung (5)

Modalities

mixed (52), small molecule (44), other (6), protein or peptide (3), antibody (2)

Companies

Revolution Medicines (6) TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (3) Anocca AB (3) Quanta Therapeutics (3) Roche (3) Eli Lilly (3) Bristol-Myers Squibb (2) Zhejiang University (2) Amgen (2) Novartis (2) Astellas (2) National Cancer Institute (NCI) (2) Abbisko Therapeutics (2) Ranok Therapeutics (Hangzhou) (2) Tao Zhang (2) Incyte (2) D3 Bio (Wuxi) (2) Adlai Nortye Biopharma (2) Jiangsu HengRui Medicine (2) Ting Deng (2)

Related targets

NRAS (9) HRAS (6) PIK3CA (2) PTEN (1) BRAF (1) CRAF (1) CEACAM5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.